Meeting
2022 ASCO Annual Meeting
Efficacy of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer in phase 3 PRIME study: A subgroup analysis by response to first-line platinum-based chemotherapy.
Authors
Rutie Yin
Department of Gynecology and Obstetrics, and Key Laboratory of Obstetrics and Gynecologic and Pediatric Diseases and Birth Defects of the Ministry of Education, West China Second University Hospital, Sichuan University, Chengdu, China
Rutie Yin , Ning Li , Lingying Wu , Jing Wang , Jianqing Zhu , Lingya Pan , Beihua Kong , Hong Zheng , Jihong Liu , Xiaohua Wu , Li Wang , Yi Huang , Ke Wang , Dongling Zou , Hongqin Zhao , Chunyan Wang , Weiguo Lu , Xiaoa Zhen , Wenzhao Hang , Jianmei Hou
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT03709316
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 5551)
DOI
10.1200/JCO.2022.40.16_suppl.5551
Abstract #
5551
Poster Bd #
430
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Maintenance olaparib plus bevacizumab (bev) after platinum-based chemotherapy plus bev in patients (pts) with newly diagnosed advanced high-grade ovarian cancer (HGOC): Efficacy by BRCA1 or BRCA2 mutation in the phase III PAOLA-1 trial.
First Author: Domenica Lorusso
Poster
2019 ASCO Annual Meeting
Maintenance olaparib after platinum-based chemotherapy in patients (pts) with newly diagnosed advanced ovarian cancer (OC) and a BRCA mutation (BRCAm): Efficacy by surgical and tumor status in the Phase III SOLO1 trial.
First Author: Cara Amanda Mathews
Poster
2024 ASCO Annual Meeting
REZILIENT3: Phase 3 study of zipalertinib plus chemotherapy in patients with previously untreated, advanced nonsquamous non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) mutations.
First Author: Helena Alexandra Yu
Poster
2023 ASCO Annual Meeting
Efficacy of subsequent therapies in patients (pts) with advanced ovarian cancer (AOC) in the phase III PAOLA-1/ENGOT-ov25 trial according to whether disease progression occurred during or after the end of olaparib (ola) maintenance.
First Author: Philipp Harter